Form 8-K - Current report:
SEC Accession No. 0001367644-25-000087
Filing Date
2025-03-31
Accepted
2025-03-31 08:06:39
Documents
15
Period of Report
2025-03-31
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20250331.htm   iXBRL 8-K 27685
2 EX-99.1 a20250331pressrelease.htm EX-99.1 9647
6 imagea.jpg GRAPHIC 7489
  Complete submission text file 0001367644-25-000087.txt   174505

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20250331.xsd EX-101.SCH 1848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20250331_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20250331_pre.xml EX-101.PRE 12564
17 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20250331_htm.xml XML 2722
Mailing Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879
Business Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 25789004
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)